Drug Discovery Platforms

Targeted Oncology Pipelines

The biofoundry integrates tissue arrays with automated screening infrastructure to evaluate patient-specific responses across several targeted pipelines:

• Patient-Derived Tumor Models: Ex-vivo modeling of patient-derived cell lines to predict drug response profiles.
• Glioblastoma (GBM) Organoids: Blood-brain-barrier microfluidic models mimicking invasive glioblastoma behaviors.
• Pancreatic Ductal Adenocarcinoma (PDAC): Multi-lineage screening to evaluate microenvironment chemotherapeutic resistance.

High-Throughput Compound Screening Workflows

Traditional flat 2D cell cultures fail to replicate the spatial complexity, cell-cell interactions, and oxygen/nutrient gradients of solid tumors in vivo, leading to high failure rates in preclinical drug pipelines. The Organoid BioFoundry addresses this bottleneck by providing automated, high-throughput organoid screening platforms that mimic the physical and biochemical properties of human tissues.

Our workflow integrates high-density multi-well plates (384-well formats) with robotic liquid handlers and environmental control systems. Once organoids reach morphological maturity, they are subjected to automated compound dosing. The robotic systems can deliver nanoliter volumes of compounds across a wide range of concentrations, generating multi-point dose-response curves.

To evaluate compound efficacy in real-time, the system utilizes non-invasive optical and metabolic sensors. Confocal imaging systems measure cell death and morphological changes by capturing fluorescent markers of apoptosis and membrane leakage. Simultaneously, microfluidic sensors monitor changes in glucose consumption and lactate production, providing immediate indicators of metabolic disruption. By combining high-resolution spatial imaging with metabolic readouts, we can evaluate the tissue's response in real-time, helping pharmaceutical partners identify candidates with high efficacy and low off-target toxicity.

Regulatory Compliance and Ethical Sourcing

Utilizing human-derived tissues for drug discovery requires strict adherence to international regulatory frameworks and bioethical standards. The BioFoundry enforces a comprehensive compliance check on all genetic lines used within our systems.

First, all patient-derived donor cell lines are obtained through validated clinical partners with verified Institutional Review Board (IRB) approval. Donor consent agreements must explicitly cover the genetic reprogramming of somatic cells to induced pluripotent stem cells (iPSCs), their subsequent differentiation into 3D organoids, and their usage in commercial drug discovery workflows.

Second, we maintain genetic privacy by using de-identified cell lines. Each line is assigned a unique, secure identifier, and all genetic sequencing data is stored in encrypted databases accessible only to authorized personnel.

Third, the BioFoundry cleanroom facility operates under Biosafety Level 2 (BSL-2) containment parameters. All fluid waste is treated with virucidal agents prior to autoclaving, and all exhaust air is passed through medical-grade HEPA filters. This ensures full biosecurity and safety compliance, meeting the requirements of international regulatory bodies (FDA, EMA) for preclinical drug validation studies.

Enterprise Procurement & Inquiries

Submit a secure procurement inquiry. All responses are routed directly to the lead ingestion plane.